Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.

Polski przeglad chirurgiczny - 1 Jul 2014

Osuch Czesław, Rutkowski Piotr, Brzuszkiewicz Karolina, Bylina Elżbieta, Limon Janusz, Siedlecki Janusz A

Abstract excerpt

UNLABELLED: GIST is the most common mesenchymal tumour of gastrointestinal tract arising from mutation of KIT or PDGFRA gene. Surgery is the primary method of treatment, however a targeted therapy with imatinib is necessary due to recurrence. The aim of the study was to evaluate efficacy of the targeted chemotherapy in advanced gastrointestinal stromal tumours with non-exon 11 KIT mutations. MATERIAL AND METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Disease Progression

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Predictive Value of Tests

Share to Sex Factors

Source

Identifiers

PMID: 25222580
DOI: 10.2478/pjs-2014-0057

Genes

KIT
PDGFRA

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.PMID 25222580Read ↗

Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis.Semantic proximity Read ↗

Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.Semantic proximity Read ↗

[Therapeutic targets in gastrointestinal stromal tumors].Semantic proximity Read ↗

Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.Semantic proximity Read ↗

Exon 11 homozygous mutations and intron 10/exon 11 junction deletions in the KIT gene are associated with poor prognosis of patients with gastrointestinal stromal tumors.Semantic proximity Read ↗

Neoadjuvant Imatinib in Locally Advanced Gastrointestinal stromal Tumours, Will Kit Mutation Analysis Be a Pathfinder?Semantic proximity Read ↗

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.Semantic proximity Read ↗

Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.Semantic proximity Read ↗

KIT gene mutations in gastrointestinal stromal tumor.Semantic proximity Read ↗

Targeted therapy and personalized medicine in gastrointestinal stromal tumors: drug resistance, mechanisms, and treatment strategiesSemantic proximity Read ↗

Clinical and Prognostic Significance of KIT exon 11 Mutation and Ki-67 Expression in Primary Gastrointestinal Stromal Tumor (GIST)Semantic proximity Read ↗

Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.